CVEvulnerability
CVE-2026-15415
6.8 MEDIUM
Official page ↗
- Status
- Awaiting Analysis
- Published
- 2026-07-17
- Last modified
- 2026-10-24
- Assigner
- ff89ba41-3aa1-4d27-914a-91399e9639e5
- CVSS 4.0 (ff89ba41-3aa1-4d27-914a-91399e9639e5)
- 6.8 MEDIUM — CVSS:4.0/AV:L/AC:L/AT:N/PR:N/UI:P/VC:N/VI:H/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
- CVSS 3.1 (ff89ba41-3aa1-4d27-914a-91399e9639e5)
- 5.5 MEDIUM — CVSS:3.1/AV:L/AC:L/PR:N/UI:R/S:U/C:N/I:H/A:N
- Weaknesses
- CWE-23
Description
AWS HealthOmics is a HIPAA-eligible service that fully manages the compute, storage, and workflow engine infrastructure required to run bioinformatics analyses at scale for clinical diagnostics, drug discovery, and agricultural research.
Improper limitation of a pathname to a restricted directory in the linting tools of the AWS HealthOmics MCP Server (aws-healthomics-mcp-server) before version 0.0.36 might allow an actor who can influence the MCP agent to write an actor-controlled content to arbitrary locations outside the intended workflow bundle directory, via directory traversal sequences in the workflow_files input.
To remediate this issue, users should upgrade to version 0.0.36 or later.
Related
Weakness · CWE (1)
- CWE-23 Relative Path Traversal weakness